as 07-26-2024 4:00pm EST
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.
Founded: | 2011 | Country: | United States |
Employees: | N/A | City: | WATERTOWN |
Market Cap: | 568.2M | IPO Year: | 2020 |
Target Price: | $33.75 | AVG Volume (30 days): | 331.0K |
Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -3.78 | EPS Growth: | N/A |
52 Week Low/High: | $8.20 - $18.75 | Next Earning Date: | 08-06-2024 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | -73.68% | Revenue Growth (next year): | 184.62% |
ITOS Breaking Stock News: Dive into ITOS Ticker-Specific Updates for Smart Investing
Pharmaceutical Technology
17 days ago
MT Newswires
18 days ago
GlobeNewswire
19 days ago
MT Newswires
21 days ago
Clinical Trials Arena
a month ago
GlobeNewswire
a month ago
Simply Wall St.
2 months ago
MT Newswires
2 months ago
The information presented on this page, "ITOS iTeos Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.